278 related articles for article (PubMed ID: 32413929)
1. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer.
Wilken R; Criscito M; Pavlick AC; Stevenson ML; Carucci JA
Facial Plast Surg; 2020 Apr; 36(2):200-210. PubMed ID: 32413929
[TBL] [Abstract][Full Text] [Related]
2. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
3. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
4. Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.
Grund-Gröschke S; Ortner D; Szenes-Nagy AB; Zaborsky N; Weiss R; Neureiter D; Wipplinger M; Risch A; Hammerl P; Greil R; Sibilia M; Gratz IK; Stoitzner P; Aberger F
Mol Oncol; 2020 Sep; 14(9):1930-1946. PubMed ID: 32615027
[TBL] [Abstract][Full Text] [Related]
5. New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma.
Villani A; Potestio L; Fabbrocini G; Scalvenzi M
Adv Ther; 2022 Mar; 39(3):1164-1178. PubMed ID: 35089534
[TBL] [Abstract][Full Text] [Related]
6. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer.
Chen L; Aria AB; Silapunt S; Migden MR
Dermatol Surg; 2019 Jan; 45(1):1-16. PubMed ID: 30045105
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
8. Investigative Landscape in Advanced Non-Melanoma Skin Cancers.
Reddy P; Yao M; Patel M
Curr Treat Options Oncol; 2021 Jun; 22(7):56. PubMed ID: 34097150
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer.
Aboul-Fettouh N; Kubicki SL; Chen L; Silapunt S; Migden MR
Dermatol Clin; 2023 Jan; 41(1):23-37. PubMed ID: 36410980
[TBL] [Abstract][Full Text] [Related]
11. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer.
Rubatto M; Sciamarrelli N; Borriello S; Pala V; Mastorino L; Tonella L; Ribero S; Quaglino P
Front Med (Lausanne); 2022; 9():959289. PubMed ID: 36844955
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?
Moujaess E; Merhy R; Kattan J; Sarkis AS; Tomb R
Immunotherapy; 2021 Oct; 13(15):1293-1304. PubMed ID: 34463126
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes.
Shalhout SZ; Kaufman HL; Emerick KS; Miller DM
Clin Cancer Res; 2022 Jun; 28(11):2211-2220. PubMed ID: 35121622
[TBL] [Abstract][Full Text] [Related]
14. Sonidegib phosphate: new approval for basal cell carcinoma.
Tibes R
Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
[TBL] [Abstract][Full Text] [Related]
15. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Hooiveld-Noeken JS; Eggen AC; Rácz E; de Vries EGE; Reyners AKL; Jalving M
Crit Rev Oncol Hematol; 2022 Dec; 180():103855. PubMed ID: 36257534
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
17. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
18. Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors.
Weiss GJ; Korn RL
Cancer; 2012 Nov; 118(21):5310-9. PubMed ID: 22511370
[TBL] [Abstract][Full Text] [Related]
19. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
20. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M
Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]